10 Depression Clinical Trials in Glendale, AZ (2026)

Q: How do I join a clinical trial in Glendale?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Glendale research site will contact you.

Recruiting Depression Studies in Glendale

NCT06966401Recruiting

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD....

Glendale, AZPHASE3850 participantsNeurocrine Biosciences

View Study Details

NCT06559306Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant i...

Glendale, AZPHASE3752 participantsJanssen Research & Development, LLC

View Study Details

NCT06775379Recruiting

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants ...

Glendale, AZPHASE3450 participantsXenon Pharmaceuticals Inc.

View Study Details

NCT07065240Recruiting

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive diso...

Glendale, AZPHASE2360 participantsSeaport Therapeutics

View Study Details

NCT06793397Recruiting

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD....

Glendale, AZPHASE3330 participantsCybin IRL Limited

View Study Details

NCT05922878Recruiting

Study of ALTO-300 in MDD

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics....

Glendale, AZPHASE2321 participantsAlto Neuroscience

View Study Details

NCT06633016Recruiting

Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who ha...

Glendale, AZPHASE2230 participantsAutobahn Therapeutics, Inc.

View Study Details

NCT06911112Recruiting

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression....

Glendale, AZPHASE3200 participantsNeurocrine Biosciences

View Study Details

NCT07284667Recruiting

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatmen...

Glendale, AZPHASE2153 participantsACADIA Pharmaceuticals Inc.

View Study Details

NCT06524830Recruiting

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatm...

Glendale, AZPHASE2142 participantsatai Therapeutics, Inc.

View Study Details

About Depression Clinical Trials in Glendale

Depression (major depressive disorder) is a common and serious mood disorder that negatively affects how you feel, think, and handle daily activities. It affects over 280 million people globally. Treatment includes psychotherapy, antidepressant medications, and brain stimulation therapies.

There are currently 10 depression clinical trials recruiting participants in Glendale, AZ. These studies are seeking a combined 3,788 participants. Research is being sponsored by Neurocrine Biosciences, Janssen Research & Development, LLC, Xenon Pharmaceuticals Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Depression Clinical Trials in Glendale — FAQ

Are there depression clinical trials in Glendale?

Yes, there are 10 depression clinical trials currently recruiting in Glendale, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Glendale?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Glendale research site will contact you about next steps.

Are clinical trials in Glendale free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Glendale studies also compensate for your time and travel.

What depression treatments are being tested?

The 10 active trials in Glendale are testing new therapies including novel drugs, biologics, and treatment approaches for depression.

Data updated July 22, 2026 from ClinicalTrials.gov